[1.]Balderas F, Casillas R, Saavedra E, et al. Adult-onset Still's disease. Best Practice & Research Clinical Rheumatology 2014;13(5-6):708-722.
[2.]Guerrieri A, Angeletti G, Mazzolini M, et al. Pulmonary involvement in adult Still's disease: Case report and brief review of literature. Respiratory medicine case reports 2017;22:91-94. doi: 10.1016/j.rmcr.2017.07.001
[3.]Bracaglia C, Prencipe G, De Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatric rheumatology online journal 2017;15(1):5. doi: 10.1186/s12969-016-0130-4
[4.]Kumakura S, Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis & rheumatology 2014;66(8):2297-2307. doi: 10.1002/art.38672
[5.]Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med 2015;66:145-159. doi: 10.1146/annurev-med-061813-012806
[6.]Yildiz H, Bailly S, Van Den Neste E, et al. Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies. Therapeutics and clinical risk management 2021;17:293-304. doi: 10.2147/TCRM.S195538 [published Online First: 2021/04/24]
[7.]Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Annals of the rheumatic diseases 2018;77(12):1720-1729. doi: 10.1136/annrheumdis-2018-213920 [published Online First: 2018/10/04]
[8.]Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol 2019 doi: 10.1016/S2352-3026(19)30156-5 [published Online First: 2019/09/21]
[9.]Ehl S, Astigarraga I, von Bahr Greenwood T, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract 2018;6(5):1508-1517. doi: 10.1016/j.jaip.2018.05.031 [published Online First: 2018/09/12]
[10.]Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48(2):124-131. doi: 10.1002/pbc.21039
[11.]La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 2019;133(23):2465-2477. doi: 10.1182/blood.2018894618 [published Online First: 2019/04/18]
[12.]Sung L, King SM, Carcao M, et al. Adverse outcomes in primary hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2002;24(7):550-554.
[13.]Gupta AA, Tyrrell P, Valani R, et al. Experience with hemophagocytic lymphohistiocytosis/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol 2009;31(2):81-84. doi: 10.1097/MPH.0b013e3181923cb4
[14.]Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. The New England journal of medicine 2020;382(19):1811-1822. doi: 10.1056/NEJMoa1911326 [published Online First: 2020/05/07]
[15.]Ravelli A, Minoia F, Davi S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis & rheumatology 2016;68(3):566-576. doi: 10.1002/art.39332
[16.]Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program 2009:127-131. doi: 10.1182/asheducation-2009.1.127 [published Online First: 2009/12/17]
[17.]Ahn SS, Yoo BW, Jung SM, et al. Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease. The Journal of rheumatology 2017;44(7):996-1003. doi: 10.3899/jrheum.161286
[18.]Jamilloux Y, Gerfaud-Valentin M, Henry T, et al. Treatment of adult-onset Still's disease: a review. Therapeutics and clinical risk management 2015;11:33-43. doi: 10.2147/TCRM.S64951
[19.]Wang R, Li T, Ye S, et al. Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis. Clinical rheumatology 2020;39(8):2379-2386. doi: 10.1007/s10067-020-04949-0 [published Online First: 2020/03/05]
[20.]Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. Journal of immunology 2014;192(1):84-91. doi: 10.4049/jimmunol.1302282 [published Online First: 2013/11/22]